

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
ALLIA.143CP2

APPLICATION NO.
09/111,123

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Habib Zaghouani

FILING DATE
July 6, 1998

GROUP
1644

TECH CENTER 1600/2900

MAR 19 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
				530	387.3	12/22/94

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
PN	1 Adorini, et al., <i>New Perspectives on Immunointervention in Autoimmune Diseases</i> , Immunol. Today, 11(11):383-386 (1990).
	2 Endoh, et al., <i>Studies of Experimental Allergic Encephalomyelitis in Old Mice</i> , J. of Neuroimmunol., 29:21-31 (1990).
	3 Muller, et al., <i>Selective in vivo Inhibition of T Cell Activation by Class II MHC-Binding Peptides Administered in Soluble Form</i> , J. Immunol., 145(12):4006-4011 (1990).
	4 Takemori, et al., <i>Mechanism of Neonatally Induced Idiotype Suppression and its Relevance for the Acquisition of Self-tolerance</i> , Immunological Reviews, 79:103-117, (1984)

S:\DOCS\SGJ\SGJ-1438.DOC:dmb
020702

EXAMINER	<i>Patrycja J. NOL</i>	DATE CONSIDERED	<i>11/10/03</i>
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ALLIA.143CP2APPLICATION NO.
09/111,123INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Habib ZaghouaniFILING DATE
July 6, 1998GROUP
1644

TECH CENTER 600/2900

FEB 01 2002

RECEIVED

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
PN	1	5,969,109	10/19/99	Bona, et al.	530	387.3	12/22/94

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PN	2	WO 96/19584	06/27/96	PCT			
	3	WO 98/30706	07/16/98	PCT			
	4	WO 99/09064	02/25/99	PCT			
	5	WO 00/01732	01/13/00	PCT			

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

PN	6	Arnold et al., Multiple Levels of Peripheral Tolerance, Immunol. Today, 14:12-14 (1993).
	7	Fowlkes et al., T-Cell Tolerance, Curr. Opin. Immunol., 5:873-879 (1993).
	8	Gosselin, et al., Enhanced Antigen Presentation Using Human FcγRI Receptor (Monocyte/Macrophage)-Specific Immunogens, J. Immunol., 149(11):3477-3481 (1992).
	9	Jenkins et al., Molecules Involved in T-Cell Costimulation, Curr Opin. Immunol., 5:361-367 (1993).
	10	Kosaka et al., Tolerance of CD8+ T Cells Developing in Paren F1 Chimeras Prepared with Supralethal Irradiation: Step-Wise Induction of Tolerance in the Intrathymic and Extrathymic Environments, J. Exp. Med., 177:367-378 (1993).
	11	Legge, et al., (1997) Presentation of a T-cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or protein requiring endocytic processing, J. Exp. Med., 185(6):1043-1053. ✓
	12	Liu, C. et al., (1996) FcγRI-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes, J. Clin. Invest., 98(9):2001-2007.
	13	Ma, et al., Inhibition of Collagen-Induced Arthritis in Mice by Viral IL-10 Gene Transfer, J. Immunol, 161:1516-1524 (1998).
	14	Mathisen et al., Treatment of Experimental Autoimmune Encephalomyelitis with Genetically Modified Memory T Cells, J. Exp. Med., 186:159-164 (1997).
	15	McCormack et al., Profound Deletion of Mature T Cells in Vivo by Chronic Exposure to Exogenous Superantigen, J. Immunol., 150:3785-3792 (1993).
	16	Min, B. et al., (1998) Neonatal Exposure to a Self-Peptide-Immunoglobulin Chimera Circumvents the Use of Adjuvant and Confers Resistance to Autoimmune Disease by a Novel Mechanism Involving Interleukin 4 Lymph Node Deviation and Interferon γ-mediated Splenic Anergy, J. Exp. Med., 188(11):2007-2017.
	17	Riechmann, et al., Reshaping human antibodies for therapy. Nature. Vol. 332, March 24:323-327 (1988).
	18	Rocha et al., Peripheral Selection of the T Cell Repertoire, Science (Washington, D.C.), 251:1225-1228 (1991).


EXAMINER

Pat. J. Noz

DATE CONSIDERED

1/10/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ALLIA.143CP2	APPLICATION NO. 09/111,123
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT Habib Zaghouani	
		FILING DATE July 6, 1998	GROUP 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN	19	Shaw, et al., Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis, <i>J. Exp. Med.</i> , 185:1711-1714 (1997).
	20	Sollazzo, et al., Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding. <i>Protein Engineering</i> , 4(2):215-220 (1990).
	21	Tuohy et al., The Epitope Spreading Cascade During Progression of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. <i>Immunol. Rev.</i> , 164:93-100 (1998).
	22	Webb et al., Extrathymic Tolerance of Mature T Cells: Clonal Elimination as a Consequence of Immunity, <i>Cell.</i> , 63:1249-1256 (1990).
	23	Zaghouani et al., Cells Expressing an H Chain Ig Gene Carrying a Viral T Cell Epitope are Lysed by Specific Cytolytic T Cells, <i>J. Immunol.</i> , 148:3604-3609 (1992).
	24	Zaghouani et al., Presentation of a Viral T Cell Epitope Expressed in the CDR3 Region of a Self Immunoglobulin Molecule, <i>Science</i> , 259:224-227 (1993).
	25	Zaghouani et al., Induction of Antibodies to the Envelope Protein of the Human Immunodeficiency Virus by Immunization with Monoclonal Anti-Idiotypes, <i>Proc. Natl. Acad. Sci USA.</i> , 88:5645-5649, (1991).
	26	Zaghouani, et al., Engineered Immunoglobulin Molecules as Vehicles for T Cell Epitopes, <i>Intern. Rev. Immunol.</i> , 10:265-278 (1993).
	27	Zaghouani, Habib, U.S. App. No. 08/779,767, filed 01/07/97, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143A.
	28	Zaghouani, Habib, 08/779,767, filed 01/07/97, Currently Pending Claims - "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143A.
	29	Zaghouani, Habib, 09/341,011, filed 10/12/99, Currently Pending Claims - "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143APC.
	30	Zaghouani, Habib, 09/623,728, filed 09/05/00, Currently Pending Claims - "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143C1.
	31	Zaghouani, Habib, U.S. App. No. 09/873,901, filed 06/04/01, entitled "Coupling of Peripheral Tolerance to Endogenous IL-10 Promotes Effective Modulation of T Cells and Ameliorates Autoimmune Disease," Docket No. ALLIA.143CP3.
	32	Zaghouani, Habib, 09/873,901, filed 06/04/01, Currently Pending Claims - "Coupling of Peripheral Tolerance to Endogenous IL-10 Promotes Effective Modulation of T Cells and Ameliorates Autoimmune Disease," Docket No. ALLIA.143CP3.
	33	Zaghouani, Habib, U.S. App. No. 10/000,868, filed 11/30/01, entitled "Coupling of Peripheral Tolerance to Endogenous IL-10 Promotes Effective Modulation of T Cells and Ameliorates Autoimmune Disease," Docket No. ALLIA.143DV1.
PN	34	International Search Report for co-pending Application No. PCT/US01/40834.

S:\DOCS\SGJ\SGJ-1297.DOC
101901

EXAMINER <i>Patman/102</i>	DATE CONSIDERED <i>11/10/03</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609: DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	